{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:20:02Z","timestamp":1747196402176,"version":"3.40.5"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Allarity Therapeutics"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Purpose<\/jats:title><jats:p>Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1\/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovitinib and was applied retrospectively.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Patients and methods<\/jats:title><jats:p>Archival tumor samples were obtained from consenting patients in a phase 3 trial comparing dovitinib to sorafenib in renal cell carcinoma patients and the DRP-Dovitinib was applied. The biomarker algorithm combines the expression of 58 messenger RNAs relevant to the<jats:italic>in vitro<\/jats:italic>sensitivity or resistance to dovitinib, including genes associated with FGFR, PDGF, VEGF, PI3K\/Akt\/mTOR and topoisomerase pathways as well as ABC drug transport, and provides a likelihood score between 0\u2013100%.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>The DRP-Dovitinib divided the dovitinib treated RCC patients into two groups, sensitive (n = 49, DRP score &gt;50%) or resistant (n = 86, DRP score \u2264 50%) to dovitinib. The DRP sensitive population was compared to the unselected sorafenib arm (n = 286). Median progression-free survival (PFS) was 3.8 months in the DRP sensitive dovitinib arm and 3.6 months in the sorafenib arm (hazard ratio 0.71, 95% CI 0.51\u20131.01). Median overall survival (OS) was 15.0 months in the DRP sensitive dovitinib arm and 11.2 months in the sorafenib arm (hazard ratio 0.69, 95% CI 0.48\u20130.99). The observed clinical benefit increased with increasing DRP score. At a cutoff of 67% the median OS was 20.6 months and the median PFS was 5.7 months in the dovitinib arm. The results were confirmed in five smaller phase II trials of dovitinib which showed a similar trend.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>The DRP-Dovitinib shows promise as a potential biomarker for identifying advanced RCC patients most likely to experience clinical benefit from dovitinib treatment, subject to confirmation in an independent prospective trial of dovitinib in RCC patients.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0290681","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T17:30:40Z","timestamp":1693416640000},"page":"e0290681","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-2504","authenticated-orcid":true,"given":"Steen","family":"Knudsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anker","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Foegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Frykman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"issue":"Suppl 2","key":"pone.0290681.ref001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2011-S2-14","article-title":"Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence","volume":"162","author":"TE Hutson","year":"2011","journal-title":"The oncologist"},{"issue":"7","key":"pone.0290681.ref002","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/ijc.32256","article-title":"Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer","volume":"145","author":"M Elgendy","year":"2019","journal-title":"International journal of cancer"},{"issue":"4","key":"pone.0290681.ref003","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1684\/ecn.2009.0175","article-title":"Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist","volume":"20","author":"P Alessi","year":"2009","journal-title":"European cytokine network"},{"issue":"15","key":"pone.0290681.ref004","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/jco.2010.28.15_suppl.4621","article-title":"Fibroblast growth factor pathway in renal cell carcinoma","volume":"28","author":"I Tsimafeyeu","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"28","key":"pone.0290681.ref005","doi-asserted-by":"crossref","first-page":"44735","DOI":"10.18632\/oncotarget.8203","article-title":"Molecular and clinical significance of fibroblast growth factor 2 (FGF2 \/bFGF) in malignancies of solid and hematological cancers for personalized therapies","volume":"7","author":"MR Akl","year":"2016","journal-title":"Oncotarget"},{"issue":"13","key":"pone.0290681.ref006","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.3390\/ijms21134691","article-title":"Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective","volume":"21","author":"D Lavacchi","year":"2020","journal-title":"International journal of molecular sciences"},{"issue":"7","key":"pone.0290681.ref007","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","article-title":"Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies","volume":"17","author":"P Makhov","year":"2018","journal-title":"Molecular cancer therapeutics"},{"issue":"4","key":"pone.0290681.ref008","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"P Sharma","year":"2017","journal-title":"Cell"},{"issue":"2","key":"pone.0290681.ref009","doi-asserted-by":"crossref","first-page":"e87415","DOI":"10.1371\/journal.pone.0087415","article-title":"Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients","volume":"9","author":"S Knudsen","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"pone.0290681.ref010","doi-asserted-by":"crossref","first-page":"e0115538","DOI":"10.1371\/journal.pone.0115538","article-title":"Development and blind clinical validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL","volume":"10","author":"S Knudsen","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"pone.0290681.ref011","doi-asserted-by":"crossref","first-page":"e0155123","DOI":"10.1371\/journal.pone.0155123","article-title":"Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data","volume":"11","author":"IK Buhl","year":"2016","journal-title":"PLoS One"},{"key":"pone.0290681.ref012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.gene.2017.10.071","article-title":"Drug response prediction in high-risk multiple myeloma","volume":"644","author":"AJ Vangsted","year":"2018","journal-title":"Gene"},{"issue":"3","key":"pone.0290681.ref013","doi-asserted-by":"crossref","first-page":"e0194609","DOI":"10.1371\/journal.pone.0194609","article-title":"Molecular prediction of adjuvant cisplatin efficacy in Non- Small Cell Lung Cancer (NSCLC)\u2014Validation in two independent cohorts","volume":"13","author":"IK Buhl","year":"2018","journal-title":"PLoS ONE"},{"key":"pone.0290681.ref014","article-title":"Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study","author":"ASK Buhl","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"pone.0290681.ref015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41416-020-0916-5","article-title":"First-in-human study of the PARP\/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor","volume":"123","author":"R Plummer","year":"2020","journal-title":"Br J Cancer"},{"key":"pone.0290681.ref016","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","volume":"15","author":"RJ Motzer","year":"2014","journal-title":"Lancet Oncol"},{"key":"pone.0290681.ref017","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.28600","article-title":"Randomized, Open-Label Phase 2 Study Comparing Frontline Dovitinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma","volume":"64","author":"AL Cheng","year":"2016","journal-title":"Hepatology"},{"key":"pone.0290681.ref018","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(15)70159-2","article-title":"Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study","volume":"16","author":"GE Konecny","year":"2015","journal-title":"Lancet Oncol"},{"key":"pone.0290681.ref019","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/bjc.2017.290","article-title":"Dovitinib in patients with gastrointestinal stromal tumour refractory and\/or intolerant to imatinib","volume":"117","author":"H Joensuu","year":"2017","journal-title":"British Journal of Cancer"},{"issue":"13","key":"pone.0290681.ref020","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer","volume":"19","author":"F Andr\u00e9","year":"2013","journal-title":"Clin Cancer Res"},{"key":"pone.0290681.ref021","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13058-017-0807-8","article-title":"Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2\u2212 breast cancer that had progressed during or after prior endocrine therapy","volume":"19","author":"A Musolino","year":"2017","journal-title":"Breast Cancer Research"},{"issue":"10","key":"pone.0290681.ref022","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-04-2129","article-title":"In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models","volume":"11","author":"S Lee","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"19","key":"pone.0290681.ref023","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"SM Wilhelm","year":"2004","journal-title":"Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0290681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T16:26:42Z","timestamp":1703089602000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0290681"}},"subtitle":[],"editor":[{"given":"Juan","family":"Sainz","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0290681","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,8,30]]}}}